Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters

Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters

Abstract Background Radiation pneumonitis (RP) is a major pulmonary adverse event of chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective subsequent‐line therapy after concurrent chemoradiotherapy (CCRT) found that patients with grade 2 or higher RP may have to be exclude...

Full description

Bibliographic Details
Main Authors: Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Norihisa Katayama, Masahiro Kuroda, Katsuyuki Kiura, Takao Hiraki, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
cisplatin/docetaxel
dose‐volume histogram
non‐small cell lung cancer
PACIFIC trial
radiation pneumonitis
Online Access:https://doi.org/10.1002/cam4.3093

Internet

https://doi.org/10.1002/cam4.3093

Similar Items